Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 1:05 PM
Ignite Modification Date:
2025-12-24 @ 1:05 PM
NCT ID:
NCT01159561
Eligibility Criteria:
Inclusion Criteria:
* 18-55 years of age
* In good health as determined by pertinent medical history, brief physical exam, vital signs, and clinical safety laboratory evaluations
* Female: has a negative urine pregnancy test and is willing to use reliable form of contraception for the study duration
* Negative HIV antibody screen, seronegative for HBsAg and Hepatitis C antibody
* WEE, EEE, VEE, and CHIK PRNT80\<1:10
* Ability to comprehend abnd a willingness to sign an informed consent, which includes the HIPAA and a separate HIV consent form
* Be willing to comply with all follow-up visits, testing, and AE reporting
Exclusion Criteria:
* Participant in the USAMRIID SIP
* Receipt of any other vaccine or investigational; drug within 30 days prior to study entry
* Anticipates receipt of other vaccines for the duration of the study (influenza vaccination will be permitted but not within 28 days of WEE vaccination
* Acute of chronic medical conditions, medications, or dietary supplements that, in the PI's opinion, would impair the subject's ability to respond to vaccination
* Hypersensitivity to any vaccine
* Allergic to any vaccine component: Human serum albumin, Neomycin
* Receipt of or anticipates receipt of blood products during the study
* Female: Pregnant or breastfeeding
* Clinically significant abnormal laboratory tests (generally greater than or equl to 2 times the upper limit of normal as determined by the PI)
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
55 Years
Study:
NCT01159561
Study Brief:
Protocol Section:
NCT01159561